These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 34148945)
1. Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report. Iwatsuka K; Kikuta D; Shibuya H; Ogawa M; Gotoda T; Moriyama M; Nakagawara H; Hemmi A; Yamao K Intern Med; 2021 Dec; 60(23):3743-3748. PubMed ID: 34148945 [TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450 [TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697 [TBL] [Abstract][Full Text] [Related]
5. Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338 [TBL] [Abstract][Full Text] [Related]
6. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140 [TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E; Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220 [TBL] [Abstract][Full Text] [Related]
8. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma. Kato A; Naiki-Ito A; Naitoh I; Hayashi K; Nakazawa T; Shimizu S; Nishi Y; Okumura F; Inoue T; Takada H; Kondo H; Yoshida M; Takahashi S; Joh T Hum Pathol; 2018 Apr; 74():92-98. PubMed ID: 29339176 [TBL] [Abstract][Full Text] [Related]
9. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636 [TBL] [Abstract][Full Text] [Related]
10. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer. John P; Butler H; Saif MW Anticancer Res; 2014 Dec; 34(12):7267-70. PubMed ID: 25503159 [TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639 [TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. Kaneko T; Sugimori K; Tozuka Y; Fukushima T; Okada K; Oka H; Okazaki H; Maeda S Clin J Gastroenterol; 2019 Oct; 12(5):484-489. PubMed ID: 30993653 [TBL] [Abstract][Full Text] [Related]
13. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Weiss GJ; Blaydorn L; Beck J; Bornemann-Kolatzki K; Urnovitz H; Schütz E; Khemka V Invest New Drugs; 2018 Feb; 36(1):96-102. PubMed ID: 29119276 [TBL] [Abstract][Full Text] [Related]
14. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641 [TBL] [Abstract][Full Text] [Related]
15. [Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case]. Kataoka K; Matsubara H; Urano F; Okamura S; Maeda M Nihon Shokakibyo Gakkai Zasshi; 2016; 113(10):1777-1784. PubMed ID: 27725467 [TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517 [TBL] [Abstract][Full Text] [Related]
17. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407 [TBL] [Abstract][Full Text] [Related]
18. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172 [TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079 [TBL] [Abstract][Full Text] [Related]
20. [Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit]. Hubault M; Faure R; Walter T; Forestier J; Lombard-Bohas C; Pivot C Bull Cancer; 2015 May; 102(5):403-4. PubMed ID: 25866372 [No Abstract] [Full Text] [Related] [Next] [New Search]